All In Biotech

Drug Trial Radar · NCT07295678

URGO FilmoCream Eczema + Dermocorticoids in Atopic Dermatitis

Open-label Clinical Investigation to Evaluate the Performance and Safety of Medical Device "Urgo Filmocream Eczema" in Association With Dermocorticoids on Atopic Dermatitis Lesions

Last checked: Nov 19, 2026Latest source record: Dec 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

44

Planned (sponsor's estimate)

Start

Jan 5, 2026

Primary completion

Jul 30, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
CEN BiotechIndustry
Sponsor type
Industry
Collaborators
Eurofins Dermscan Pharmascan; URGO Recherche, Innovation et Développement
First posted
Dec 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to determine whether URGO FilmoCream Eczema is effective as a non-steroidal treatment to relieve symptoms of atopic dermatitis. It also aims to evaluate the cream's ability to moisturize, soothe irritation, protect the skin, and promote healing of eczema lesions. The main questions the study seeks to answer are: 1. Does URGO FilmoCream Eczema improve symptom relief of atopic dermatitis when used alongside standard topical corticosteroid treatment? 2. How do eczema lesions treated with topical corticosteroids alone progress and heal compared to those treated with topical corticosteroids plus URGO FilmoCream Eczema? To investigate this, patients with at least two similar eczema lesions are enrolled. One lesion is treated with topical corticosteroids alone, while the other is treated with topical corticosteroids plus URGO FilmoCream Eczema. The progression of both lesions is monitored throughout treatment, until healing, and for 28 days after the last application of topical corticosteroids.

Conditions

  • Atopic Dermatitis

Interventions

  • Treatment period with dermocorticoid aloneDrug

    Until lesion resolution, for a maximum of 30 consecutive days Treatment with dermocorticoids - desonide 0.1%, or betamethasone 0.05% in case treatment escalation is required.

  • Treatment period with combination of URGO FilmoCream Eczema and dermocorticoidCombination product

    Until lesion resolution, for a maximum of 30 consecutive days URGO FilmoCream Eczema is applied at least twice daily (morning and evening) in a thin layer over the entire surface of the selected lesion, extending 1 cm beyond the edges, and left to dry for about 30 seconds to form a protective film. Reapplication is allowed if the film is disturbed (e.g., due to water exposure), with a maximum of 20 pump pressures per day. In the evening, it is applied after the dermocorticoid - desonide 0.1%, or betamethasone 0.05% in case treatment escalation is required.

  • Follow-up period after treatment with URGO Filmocream Eczema associated with dermocorticoidCombination product

    During the 28-day follow-up period, in case of relapse, URGO FilmoCream Eczema is reapplied twice daily (morning and evening). If there is no improvement or worsening, the combined treatment must be reinitiated under the same conditions as during the treatment period.

  • Follow-up period after dermocorticoid treatment aloneDrug

    During the 28-day follow-up period, in case of relapse, start with desonide 0.1%, escalate to betamethasone 0.05% if necessary.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in local SCORAD Index at end of treatmentTime frame: up to 30 days
  2. Change from baseline in local SCORAD Index at 3 daysTime frame: 3 days
  3. Change from baseline in local SCORAD Index at 7 daysTime frame: 7 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Eurofins Dermscan Poland

    Gdansk, Poland

  • Private Practice

    Malbork, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.